Helix BioMedix

Helix BioMedix ROE

The Return on Equity (ROE) of Helix BioMedix (HXBM) as of Nov 20, 2026 is -35.84 %. In the previous year, Return on Equity (ROE) was -47.14 % — a change of -23.97% (higher).

ROE

-35.84 %

YoY

-23.97%

Last updated:

In 2025, Helix BioMedix's return on equity (ROE) was -35.84 %, a -23.97% increase from the -47.14 % ROE in the previous year.

The Helix BioMedix ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2020
-82.76 USD
Jan 1, 2021
-28.76 USD
Jan 1, 2022
-31.34 USD
Jan 1, 2023
-35.70 USD
Jan 1, 2024
-47.14 USD
Jan 1, 2025
-35.84 USD
The Helix BioMedix ROE history
YEARROEYoY
-35.84 %-23.97%
-47.14 %+32.04%
-35.70 %+13.91%
-31.34 %+8.97%
-28.76 %-65.25%
-82.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Helix BioMedix Stock analysis

What does Helix BioMedix do? Helix BioMedix, Inc. generates revenue through the development and commercialization of its lead drug candidate HB4208, a topical treatment for Xeroderma Pigmentosum, a rare genetic disorder. The company's intellectual property portfolio enables commercialization pathways in Rx dermatology, aesthetic dermatology, and personal care, targeting patients with unmet needs in dermatological treatments. Its proprietary library of bioactive peptides, derived from the body’s innate immunity, supports the development of advanced topical formulations that address rare skin conditions while emphasizing therapeutic effectiveness and safety. The company focuses on rare dermatological diseases such as Xeroderma Pigmentosum, with HB4208 as its primary product. By leveraging its bioactive small molecule technology, Helix BioMedix aims to transform skin condition treatments through elegant, life-enhancing topical solutions. The business model centers on developing innovative therapies for niche markets where current treatments are insufficient, ensuring a targeted approach to addressing specific patient populations. Helix BioMedix is one of the most popular companies on Eulerpool.

ROE Details

Decoding Helix BioMedix's Return on Equity (ROE)

Helix BioMedix's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Helix BioMedix's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Helix BioMedix's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Helix BioMedix’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Helix BioMedix stock

Return on Equity (ROE) of Helix BioMedix is -35.84 % in 2025.

Return on Equity (ROE) of Helix BioMedix changed from -47.14 % to -35.84 %, representing a -23.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Helix BioMedix since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Helix BioMedix with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Helix BioMedix

All Key Metrics — Helix BioMedix